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Novel antivirals are needed to supplement existing control strategies for influenza A virus (IAV). A promising new class of drug,
exemplified by the compound nucleozin, has recently been identified that targets the viral nucleoprotein (NP). These inhibitors
are thought to act as “molecular staples” that stabilize interactions between NPmonomers, promoting the formation of non-
functional aggregates. Here we detail the inhibitory mechanism of nucleozin, finding that the drug has both early- and late-act-
ing effects on the IAV life cycle. When present at the start of infection, it inhibited viral RNA and protein synthesis. However,
when added at later time points, it still potently blocked the production of infectious progeny but without affecting viral macro-
molecular synthesis. Instead, nucleozin blocked the cytoplasmic trafficking of ribonucleoproteins (RNPs) that had undergone
nuclear export, promoting the formation of large perinuclear aggregates of RNPs along with cellular Rab11. This effect led to the
production of much reduced amounts of often markedly smaller virus particles. We conclude that the primary target of nu-
cleozin is the viral RNP, not NP, and this work also provides proof of the principle that IAV replication can be effectively inhib-
ited by blocking cytoplasmic trafficking of the viral genome.
The influenza A virus (IAV) genome consists of eight segmentsof negative-sense, single-stranded RNA (vRNA) that encode
10 to 14 identified proteins (1–3). Each vRNA is separately encap-
sidated into ribonucleoprotein (RNP) particles by the trimeric
viral RNA-dependent RNA polymerase (PB1, PB2, and PA) and
single-strandRNA-binding nucleoprotein (NP) (4). At the start of
infection, RNPs are released into the cytoplasm and imported into
the nucleus by the host importin alpha/beta pathway (5). Once in
the nucleus, the vRNAs are transcribed by the viral polymerase to
produce capped and polyadenylated mRNAs, as well as replicated
via an alternative plus sense transcript (cRNA). Both the cRNA
and progeny vRNAmolecules are encapsidated into RNPs, neces-
sitating the nuclear import of newly translated NP, again via in-
teractions with importin alpha (5). Once levels of the viralM1 and
NS2/NEP polypeptides are sufficient, newly synthesized RNPs are
exported to the cytoplasm via the cellular CRM1/exportin 1 path-
way (5). We and others have recently reported that RNPs accu-
mulate at the perinuclear recycling endosome (RE) after leaving
the nucleus. There, they piggyback onto Rab11-positive vesicles to
access the microtubule network for transit through the cytoplasm
(6–9). The assembly/budding phase then starts as RNPs join with
the three viral membrane proteins (hemagglutinin [HA], neur-
aminidase [NA], and M2), as well as with the M1 matrix protein
and small amounts of NS2 and the RNPs, to form new enveloped
virus particles at the apical plasma membrane (PM) (10).
Influenza virus transmission and influenza disease are partially
controlled by a global vaccination program and antiviral therapy.
The available antivirals target the ion channel protein M2 (aman-
tadine, rimantadine) or NA (oseltamivir, zanamivir), which are
responsible for entrance into and exit from the host cell, respec-
tively. However, both therapies are rendered less effective by re-
sistance (11). New antivirals developed against other IAV targets
are therefore required.One attractive strategy is to targetNP, since
this protein plays many essential roles in vRNA synthesis, genome
trafficking, and virus assembly (4, 12). Recently, several groups
identified NP-interacting molecules able to inhibit virus replica-
tion (13–17). These compounds, nucleozin or related derivatives,
bind to at least two sites on NP and appear to act as “molecular
staples” that promote the formation of higher-order oligomers or
aggregates by stabilizing monomer interactions. Evidence for this
comes from various in vitro biophysical analyses of purified NP,
cocrystallization studies with the inhibitor, and fluorescence mi-
croscopy of infected, drug-treated cells (13, 15–17). Further sup-
port for this model comes from the identification of several resis-
tance mutations in NP that map to the separate drug-binding
pockets (15–17). The drug-induced aggregation evidently inter-
feres with NP function, because the compounds potently inhibit
virus replication in tissue culture and infected animals (13, 15–
17). However, the precise mechanism(s) of action has not been
investigated in detail. While the compounds clearly inhibit viral
transcription, either from RNPs reconstituted in cells by plasmid
transfection or from RNPs purified from virus (15–17), discrep-
ancies between the 50% inhibitory concentrations for overall virus
replication versus transcription raise the possibility of more than
one mechanism of action (14).
Here we describe a distinct effect of nucleozin on the later
stages of viral infection, finding that it inhibits the cytoplasmic
transport of Rab11-RNP complexes. This is a novel mechanism of
action for any antiviral that provides proof of principle for new
strategies to interfere with viral replication.
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MATERIALS AND METHODS
Cells, viruses, antisera, and drug.Human embryonic kidney 293T, Ma-
din-Darby canine kidney (MDCK), and human alveolar basal epithelial
(A549) cells were cultured as previously described (18). Reverse-genetics-
derived A/Puerto Rico/8/34 (PR8; H1N1) was used as a model virus (19)
and titrated according to reference 20. Mutations of segment 5 (NP
Y289H) weremade, and viruses were rescued as described in reference 21.
Infections were carried out at amultiplicity of infection of 3 in serum-free
medium (SFM). After 30 min, infected cells were overlaid with SFM and
0.14% bovine serum albumin. The antibodies used included mouse
monoclonal antibodies against green fluorescent protein (GFP) (JL8;
Clontech; catalog no. 632380); GM130 (BD Transduction Laboratories;
catalog no. 610822); calnexin, EEA1, and clathrin (BD Transduction Lab-
oratories; catalog no. 610524, 610457, and 610499, respectively); LAMP1
(BD Pharmingen; catalog no. 553792); influenza virus M2 (14C2; AbCam;
catalog no. ab5416) and NA (7D8; a gift from Susanna Colaco and Phil
Stevenson); rat monoclonal anti--tubulin (YL1/2 MCA77G; AbD-Sero-
tec); and sheep polyclonal antibody to TGN46 (AbD-Serotec; catalog no.
AHP500G). The rabbit polyclonal antisera used were to whole PR8 viri-
ons, PR8 M1 (22), PB1 (V19), PA (V35) (23), PB2 (2N580) (24), and NP
(2915) (25). Anti-NS2 antibody was a gift from A. Portela. All of the
secondary antibodies used were from the Alexa Fluor range (Invitrogen).
Nucleozin (16) was dissolved in dimethyl sulfoxide and used at a concen-
tration of 1 M unless otherwise stated.
Plasmids and transfections. Plasmids encoding GFP-tagged NP (26)
or red fluorescent protein (RFP)-tagged wild-type (WT) Rab11a (6) have
been previously described. pCDNA3 plasmids used to synthesize fluores-
cence in situ hybridization (FISH) probes to detect vRNA from segments
1, 4, and 7 were described in references 22, 27, and 28, and that used to
detect mRNA for segment 5 was described in reference 29. To GFP tag
influenza virus RNPs, 1  105 293T or A549 cells were transfected with
GFP-NP (200 ng) by using Lipofectamine Plus and LTX (Invitrogen)
according to the manufacturer’s instructions, incubated overnight, and
superinfected with PR8. Cells were imaged 8 h later (unless stated other-
wise).
Microscopy. The FISH methods used to detect vRNA were described
in reference 22, and those used to detect mRNA were described in refer-
ence 29. Immunofluorescence assays were carried out as described in ref-
erence 30. Sampleswere imagedwith a Leica SP5 confocalmicroscope and
postprocessed with Adobe Photoshop and ImageJ (NIH). Single optical
sections are shown.
For live imaging, cells were grown in chambered glass bottom dishes
(Lab-Tek) and maintained at 37°C in Leibovitz L-15 CO2-independent
medium (Gibco) during analysis. Cells were transfectedwithGFP-NP and
infected with PR8 12 h later. For nucleozin treatment, images were ac-
quired for 5min and then nucleozin was added to a final concentration of
2 M before imaging for around 20 to 30 min (as stated). Images were
acquired at 0.25 or 0.71 frame/s and processed with ImageJ.
Pull-down assays,Western blotting, and primer extension analysis.
Pull-down assays of GFP-tagged proteins were performed with GFP-Trap
beads (Chromotek) as described in reference 6. Confluent six-well dishes
of 293T cells were transfected with 500 ng of each plasmid (GFP or GFP-
NP) and, where applicable, infected 12 h later with virus. All samples were
collected at 8 h postinfection (hpi). At the end of the process, bound
proteins were eluted by boiling in SDS-PAGE sample buffer, while bound
RNA was extracted by adding 1 ml of TRIzol (Invitrogen) and 200 l
chloroform directly to the Trap beads and recovered by ethanol precipi-
tation. Specific RNA species were detected by reverse transcriptase-radio-
labeled primer extension, followed by urea-PAGE and autoradiography as
described previously (31). Western blotting was performed according to
standard procedures and imaged with a LiCor Biosciences Odyssey near-
infrared platform (32).
Transmission electron microscopy (TEM). A549 cells were seeded
onto 24-well plates, transfected, and infected as described above. Cells
were washed in 0.1 MHEPES, pH 7.4, and incubated for 2 h at 4°C in 0.1
MHEPES (pH 7.4)–2% glutaraldehyde–0.1%H2O2. The monolayer was
washed with HEPES buffer, and cells were scraped into buffer and har-
vested by centrifugation at 14,000  g for 10 min. The supernatant was
replaced with fresh HEPES buffer and processed by the Cambridge Uni-
versity Multi-Imaging Centre. Images were acquired with an FEI Philips
CM100 transmission electron microscope equipped with a Deben AMT
digital camera and an EDAX Genesis XM4 EDX system.
RESULTS
Nucleozin has distinct effects on virus replication, depending
on the time of addition. As a first test of how nucleozin inhibits
IAV replication, we examined the effects of adding the drug at
different times postinfection on the titer of replicated virus, by
using theWTPR8 virus and a derivative engineered to contain the
nucleozin resistance mutation NP Y289H. In the absence of the
drug, WT virus release was detectable by 6 hpi but was around
20-fold higher at 8 hpi. However, addition of the drug at 0.5, 2.5,
or 4 hpi decreased titers at 8 hpi by around 1,000-fold and, on
average, by 10-fold if added at 6 hpi (Fig. 1A). The NP Y289H
mutant reached similar titers in the absence or presence of the
drug but had an overall growth defect of about 10-fold compared
to the WT, as reported for the A/WSN/33 strain (16). Thus, nu-
cleozin is an effective inhibitor ofWT virus replication even when
added at relatively late times in the replication cycle.
We next tested the effect of nucleozin on WT viral macromo-
lecular synthesis over a time course of infection. Expression of
viral proteins increased over time in untreated cells, as expected
(Fig. 1B, lanes 1 to 4). When nucleozin was added at 0.5 hpi, viral
polypeptide synthesis wasmuch reduced but not completely abol-
ished, with small amounts of NP, M1, and PB2 detected at 8 hpi
(Fig. 1B, lanes 5 to 8). Inhibition of viral protein synthesis was
much less noticeable when the drug was added at 2.5 hpi (lanes 9
to 11) and was not significant when the drug was added at 4 hpi
(lanes 12 and 13), where protein expression reached the same
levels as in untreated cells. These alterations in polypeptide accu-
mulation were reflected in drug-induced changes in the abun-
dance of viralmRNAwhenPA-segment 3 andNP-segment 5 tran-
scripts were examined as examples. In untreated cells, viralmRNA
peaked at 4 hpi and declined thereafter (Fig. 1C, lanes 1 to 4), as
previously observed (28, 31). When the drug was added at the
beginning of infection, transcript accumulation was much de-
layed and reduced (lanes 5 to 8), but this effect was not seen when
the compound was added at 2.5 or 4 hpi (lanes 9 to 13). Notably,
this failure to inhibitmRNAproductionwhen the drug was added
later was seen even when the compound was added before sub-
stantial amounts of transcription had occurred (compare lanes 1
and 2 with lanes 9 and 10). Synthesis of vRNA followed a kinetic
pattern similar to that of the viral proteins, with detectable and
increasing synthesis from 4 hpi in normal cells (Fig. 1C, lanes 1 to
4) thatwasmarkedly reducedwhennucleozinwas added at 0.5 hpi
(lanes 5 to 8). Limited (25% of normal) vRNA synthesis was
seen when the drug was added at 2.5 hpi, with a relatively early
peak at 4 hpi and little increase thereafter (lanes 9 to 11). With
later time points of drug addition, only minimal inhibition of
vRNA synthesis was seen; quantification of replicate experiments
with the WT virus showed a less-than-2-fold decrease when the
drug was added at 4 or 6 hpi (Fig. 1C and D). The NP Y289H
mutant produced similar levels of vRNAat 8 hpi, independently of
the time of addition of the drug (Fig. 1D).
Therefore, nucleozin showed two distinct effects on virus rep-
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lication, depending on the time of addition. When added early in
infection, it inhibited the synthesis of all classes of viral RNA and
(if added early enough to block transcription) viral proteins.
However, when the drug was added later in infection, at 4 hpi
or later, viral macromolecular synthesis seemed near normal
and yet the drug still profoundly inhibited the release of infec-
tious viral particles, a differential effect that could be clearly
seen when the relative effects of the time of drug addition on
vRNA accumulation and the titer of the released virus were
compared (Fig. 1A and D).
Nucleozin aggregates outgoing viral RNPs (vRNPs) and
Rab11 in the cytoplasm. Previous work has suggested two mech-
anisms of action for nucleozin: direct inhibition of RNP transcrip-
tion, or a block to NP trafficking, postulated to be prior to nuclear
import and RNP assembly (13, 15–17). However, neither mecha-
nism seemed a plausible explanation of the late-acting drug effect,
since vRNA synthesis, and therefore, by extrapolation, RNP for-
mation, was near normal. Furthermore, after 5 hpi, the major
flow of NP is from the nucleus to the cytoplasm (33, 34). Accord-
ingly, to better understand the effect of nucleozin on NP/RNP
trafficking, we infected A549 cells with the WT virus and the NP
Y289Hmutant virus and followed the localization of NP (used as
a proxy for vRNPs) by indirect immunofluorescence assay during
the later stages of infection.We also double stained cells for Rab11,
since vRNPs use Rab11-positive vesicles to reach the PM (6–9). In
untreated cells infected with the WT virus, NP localized in the
nucleus early in infection and then accumulated in the cytoplasm,
where it colocalized with Rab11 at both 6 and 8 hpi (Fig. 2A; see
high-magnification images in Fig. S1 in the supplemental mate-
rial), as previously observed (6–9). When the WT virus was
treatedwith nucleozin at 4 hpi (andfixed at 8 h),NP accumulation
in the cytoplasm was retarded and confined largely to the perinu-
clear region, where it colocalized with a small proportion of
Rab11. The majority of Rab11 staining was, however, distributed
throughout the cytoplasm. Similar nuclear retention of NP was
seen when nucleozin was added at 6 hpi and incubated for a fur-
ther 2 h prior to fixation of the cells but with the striking addition
of large juxtanuclear accumulations of cytoplasmic staining that
colocalized strongly with Rab11 at lowmagnification (Fig. 2A). At
higher magnification, NP staining was more pronounced toward
the exterior of these structures and Rab11 staining was more pro-
nounced in their interior (see Fig. S1 in the supplemental mate-
rial). However, the distribution of Rab11 was not altered by the
presence of the drug in uninfected cells, even when it was present
for 4 h (Fig. 2A; see Fig. S1), nor were any differences in the local-
ization of either NP or Rab11 observed in the NP Y289H mutant
in the presence or absence of nucleozin (see Fig. S1).
Nucleozin-induced cytoplasmic aggregates of NP have been
noted before but interpreted to be newly synthesized NP on the
way into the nucleus (13, 16, 17). However, the timing of the effect
we observed, as well as the inclusion of Rab11 in the aggregates
(Rab11 interacts with RNPs but not non-RNP NP [6, 9]), sug-
gested that the drug was altering the trafficking of RNPs. To test
this, we used FISH to examine the localization of vRNA. As ex-
pected, in untreated cells, the three genomic segments examined
(1, 4, and 7) progressed from early accumulation in the nucleus at
4 hpi to a later punctate distribution in the cytoplasm with a pe-
rinuclear focus (Fig. 2B). However, as observed for NP, when
nucleozin was added at either 4 or 6 hpi (and cells were fixed at 8
hpi), prominent cytoplasmic aggregates of vRNA were seen sur-
FIG 1 Time-of-addition experiments examining the effect of nucleozin on IAV replication and macromolecular synthesis. (A) A549 cells were infected with
either theWTor theNPY289Hmutant virus, and 1Mnucleozin (NCZ)was added at the indicated time points. Supernatants were collected and plaque titrated
inMDCKcells. Virus titers (white bars) are expressed as themean percentage the standard deviation (n 3). (B)Cell lysates were analyzed byWestern blotting
for the indicated proteins. (C) Total cellular RNA was extracted and analyzed by radioactive primer extension, urea-PAGE and autoradiography for mRNA and
vRNA from segments 3 and 5, as well as 5S rRNA. (D) vRNA accumulationwas quantified by densitometry of primer extension autoradiographs with ImageJ and
plotted as the mean percentage of the amount from untreated cells at 8 hpi the standard deviation (n 3).
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rounding the nucleus (Fig. 2B). Furthermore, this effect was spe-
cific for vRNA, because when similarly treated cells were double
stained by FISH for segment 3 vRNA and segment 7 mRNA, no
drug-induced alterations of mRNA localization were apparent
and there was no significant cytoplasmic colocalization of the two
senses of vRNA under any condition (see Fig. S2 in the supple-
mental material). Thus, nucleozin has a late-acting effect of caus-
ing the cytoplasmic aggregation of viral genomic RNPs along with
cellular Rab11.
The prominent cytoplasmic aggregates of NP and vRNA
clearly reflected the disruption of normal RNP trafficking, so we
next tested if this resulted from the drug “dismantling” assembled
RNPs. For this, we used a system inwhich cells are transfectedwith
GFP-NP and superinfected with virus to produce GFP-tagged
RNPs that can be affinity purified or followed by live-cell micros-
copy (6). Cells were infected with PR8 virus 12 h after GFP or
GFP-NP transfection, treated (or not) with nucleozin at 6 hpi, and
lysed at 8 hpi. Aliquots of the cell lysates were then examined by
Western blotting for proteins of interest or by radioactive reverse
transcriptase primer extension reactions for RNA before or after
affinity fractionation over GFP-Trap beads. Examination of un-
fractionated cell lysate showed that GFP and GFP-NP were ex-
pressed as expected and that all of the viral proteins tested were
present in the supernatant of infected cells in equal quantities, as
was the cellular protein -tubulin (Fig. 3, lanes 1 to 6). Primer
extension reactions confirmed that segment 3 vRNA and cellular
5S rRNA were also present in approximately equal quantities.
When GFP-NP (but not GFP) was affinity purified, the NP and
FIG 2 Nucleozin induces cytoplasmic aggregates containing RNP and Rab11. A549 cells were infected with the WT virus or mock infected and either left
untreated or treated with 1 M nucleozin as shown. Samples were fixed at the times shown and stained for Rab11 and NP (A) or processed for FISH for the
indicated vRNAs (B) before imaging by confocal microscopy. Merged images include a 4=,6-diamidino-2-phenylindole (DAPI) channel shown in blue. Scale
bars, 10 m. Images are representative of three independent experiments.
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polymerase components of RNPs were coprecipitated equally in
the absence and presence of nucleozin (lanes 7 to 9 and 11).More-
over, primer extension analysis detected vRNA but not 5S rRNA
when GFP-NP was purified. Thus, the system successfully de-
tected RNP formation and this was not substantially changed by
nucleozin treatment. We also tested for the coprecipitation of
other viral structural proteins, M1 and NS2, both known to inter-
act with RNPs during nuclear export and virion assembly (5), and
M2. A small proportion ofM1was selectively purified by GFP-NP
(Fig. 3, lanes 7 and 8), but no detectable amounts of NS2 or M2
were precipitated with or without drug treatment. Nucleozin
therefore induces the cytoplasmic aggregation of RNPs but not
other viral proteins.
Nucleozin impairs the trafficking of circulating RNPs in the
cytoplasm. Nucleozin induces aggregation of vRNPs in the peri-
nuclear RE area, a region of the cell hypothesized to represent a
“way station” for transport of the virus genome from the nucleus
to the apical PM (6, 8, 9). To test if nucleozin blocked onward
transport from the RE, we acquired images of living virus-infected
cells containing GFP-NP-tagged RNPs, as well as RFP-Rab11.
A549 cells were transfected with GFP-NP and RFP-Rab11, in-
fected with PR8 virus or mock infected 12 h later, and imaged at 8
hpi. Inspection of still images of uninfected cells showed that
GFP-NP localized mostly in the nucleus, while RFP-Rab11 was
dispersed throughout the cytoplasm but with a prominent peri-
nuclear concentration, probably representing the RE (Fig. 4A).
Examination of time-lapse movies showed that both nucleoplas-
mic GFP-NP and cytoplasmic RFP-Rab11 were highly mobile but
did not coincide substantially (see the first 4.5 min of Movie S1 in
the supplemental material). When cells were infected, a distinct
population of GFP-NP was seen as punctate objects in the cyto-
plasm that colocalized with Rab11 (Fig. 4B). Time-lapse movies
showed that these too were highly mobile bodies, often forming
filamentous or tubular structures. This pattern of movement was
stable under imaging conditions for at least 25 min (Fig. 4B; see
Movie S2). On the basis of prior work in our laboratory and others
(6, 8, 9), this pattern was likely detecting GFP-NP that had been
incorporated into RNPs which, following nuclear export, were
undergoing, in part, microtubule-mediated transport courtesy of
interactions with Rab11-positive vesicles. In confirmation of this,
when cells were fixed after imaging and stained by FISH for seg-
ment 4 and 7 vRNAs, the signal colocalized with GFP-NP (data
not shown). We then tested the effect of adding nucleozin. In
mock-infected cells, drug addition had little apparent effect, in
terms of both the overall localization patterns of GFP-NP and
RFP-Rab11 (Fig. 4A) and their movement in time-lapse movies
(see min 4.5 to 29 of Movie S1). However, when the drug was
added to infected cells, the result was a dramatic loss of the small,
highly mobile GFP-NP- and RFP-Rab11-positive bodies, which
were replaced by increasingly large cytoplasmic aggregates that
still contained both proteins but that inmany cases collapsed back
onto the perinuclear region (Fig. 4C; see Movie S3). High-magni-
fication movies of vRNP-decorated vesicles moving in the cyto-
plasm of infected cells showed that they were highly mobile and
that while there were apparently continual interactions among
them, these were transient (see Fig. S3A [white arrowheads] and
Movie S4 in the supplemental material). However, in the presence
of nucleozin, interacting vesicular structures tended to remain
attached over time, thus forming large agglomerations. (see Fig.
S3B [white arrowheads] and Movie S5). Thus, nucleozin exerts a
general block to cytoplasmic transport of RNP-Rab11 complexes
by sticking vRNPs and their associated transport machinery to-
gether, most likely via NP-NP interactions.
Nucleozin does not widely disrupt the exocytic pathway in
infected cells. The components of the secretory pathway are in-
terconnected in an intricate network whereby disruption of one
pathway can have secondary effects on other vesicular pathways
(35–37). Since nucleozin disrupted Rab11 localization in infected
cells, we tested whether it has a generalized effect on the exocytic
pathway and, as a consequence, induces disruption of the traffick-
ing of viral membrane proteins. First, we tested whether the local-
ization of standard cellularmarker proteins for the secretory path-
way was altered by the addition of nucleozin at late times
postinfection. Neither endosomes (highlighted with EEA1, clath-
rin, and LAMP1), nor the endoplasmic reticulum (as assessed by
calnexin), nor the Golgi compartment (GM130 marker), nor the
trans-Golgi network (marked with TGN 46; data not shown) ag-
gregated in treated cells (Fig. 5A to C) or, indeed, noticeably
changed localization at all after drug addition (Fig. 5A and B; data
not shown for panel C). In addition, double staining for NP con-
firmed that the drug affected RNP localization as expected, but in
contrast to the result seen with Rab11 (Fig. 2A), little to no colo-
calization of the viral protein and the cellular markers was seen
(Fig. 5A to C).
FIG 3 Nucleozin treatment does not disrupt RNPs. 293T cells were trans-
fectedwith plasmids expressingGFP alone orGFP-NP, incubated for 24 h, and
infected with the WT virus or mock infected. At 6 hpi, one set of cells was
treated with 1 M nucleozin (NCZ). Cell lysates prepared at 8 hpi were ana-
lyzed byWestern blotting for the indicated polypeptides after GFP-Trap affin-
ity selection into supernatant and bound fractions. Sample loading is such that
the supernatants are equivalent to 1/10 of the bound fractions. RNA was ana-
lyzed by primer extension for segment 3 vRNA and 5S rRNA before or after
GFP-Trap selection. The experimental procedure was performed twice. Cont.,
control.
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SinceM1 andNS2/NEP are involved inRNPnuclear export (5)
and therefore might accompany the genome while it crosses the
cytoplasm, we also examined whether nucleozin affects their lo-
calization. NS2 localization did not dramatically change in the
presence of the drug (data not shown), nor did that of M1 (data
not shown).
Next, we tested the effect of nucleozin on the synthesis and
accumulation at the PMof viral transmembrane proteinsM2,NA,
and HA. By Western blotting, expression of the M2 and HA pro-
teins increased up to 8 hpi in a typical untreated time course
(Fig. 5D, lanes 1 to 3). The addition of nucleozin at either 4 or 6 hpi
had little effect on the accumulation of either protein at 8 hpi
(lanes 4 and 5), consistent with previous data showing the general
insensitivity of viral protein expression to drug addition after early
times postinfection (Fig. 1C). NA accumulation could not be sim-
ilarly assessed because of the lack of an appropriate antibody. We
then tested HA, M2, and NA localization at the PM by immuno-
fluorescence confocal microscopy. Staining of nonpermeabilized
cells for the three transmembrane proteins showed readily detect-
able levels of cell surface protein at 8 hpi (Fig. 5E and F). However,
no diminution of staining intensity or obvious differences in lo-
calization were seen after treatment with nucleozin from 6 hpi
onward. No effect on cell surface HA or M2 amounts was seen
when cells were examined by fluorescence-activated cell sorting
(data not shown). Thus, the effects of nucleozin on viral and cel-
lular trafficking pathways are apparently specific to the conjunc-
tion of RNPs and Rab11 in infected cells.
The normal trafficking of cellular and additional viral proteins
FIG 4 Live cell trafficking of GFP-NP and RFP-Rab11. A549 cells were transfected with GFP-NP and RFP-Rab11 and 12 h later infected withWT PR8 or mock
infected before imaging under time-lapse conditions (approximately every 4 s) at 8 hpi. Selected still images are shown. Arrows indicate the time of drug addition
(1 M). (A) Mock-infected cell. (B) Infected cell without drug treatment. (C) Infected cell with nucleozin treatment. Scale bars, 10 m. Images were acquired
with an SPE confocal microscope, and images were processed with LAS AF Lite. See Movies S1 to S3 in the supplemental material.
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suggests that nucleozin did not affect the function of the microtu-
bule network. Consistent with this, -tubulin staining in treated
cells was identical to that in untreated cells (Fig. 5G).
Virions budding from PM in the presence of nucleozin ex-
hibit marked defects. Nucleozin impedes the viral genome from
reaching the PM in the later stages of viral infection. To under-
stand the implications of this for virion formation, we analyzed
the WT and NP Y289Hmutant viruses by TEMwith and without
drug treatment. Budding virions of either strain were not detected
at 4 hpi (Fig. 6A). By 6 hpi, cells infected with both viruses dis-
played the characteristic features of budding virus, i.e., ellipsoidal
structures surrounded by a glycoprotein fringe, generally attached
to the PMby the tip of their shorter axis.When the budding events
in WT virus-infected cells were counted at 8 hpi, the numbers
varied around amean of 4 to 5 particles/mof PM (Fig. 6B), while
measurement of the lengths of budding virus showed a mean
long-axis dimension of 132 2.9 nm (Fig. 6C; a gallery of repre-
sentative images is shown in Fig. 6D). When nucleozin was added
at either 4 or 6 hpi to cells infected with the nucleozin-resistant virus
NP Y289H, little effect was apparent on the budding (Fig. 6A, right
hand panels) or size of the virus particles formed at 8 hpi (Fig. 6C
andD), with sizes of 113.9 2.1, 124.9 2.5, and 122.1 2.8 nm
for no drug and nucleozin addition at 4 and 6 hpi, respectively.
The WT virus, however, showed marked and distinct defects.
When the drug was added at 4 hpi, very few virions were detected
and in the rare cases where theywere observed, they had an altered
morphology, appearing much rounder, with an average height of
around 71.5  3.8 nm (Fig. 6C and D). In addition, they were
FIG 5 Nucleozin does not disrupt themain exocytic pathway. (A to C, E, F) A549 cells were infected with theWT virus, and at 6 hpi, 1Mnucleozin (NCZ) was
added to one set. Samples were fixed at 8 hpi and stained for NP and calnexin (A); NP and GM130 (B); NP and clathrin, EEA1, or LAMP1 in the presence of
nucleozin (C);M2 (E); HA (PR8) andNA (F); or NP and-tubulin (-tub) (G).Merged images include a DAPI channel shown in blue. Scale bars, 10munless
indicated otherwise. In panel D, lysates from cells treated and harvested as indicated were analyzed by Western blotting for HA, M2, and (as a loading control)
-tubulin (-tub). Images are representative of three independent experiments.
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often still attached to the PM by wide necks in amanner similar to
that seen when virus budding was inhibited through small inter-
fering RNA (siRNA)-mediated depletion of Rab11 (38).When the
drug was added at 6 hpi and the cells were fixed at 8 hpi, the
number of budding events was still very low compared to that in
untreated cells (Fig. 6B) and although some normal particles were
seen, themorphology ofmany others was abnormal;many virions
were shorter than in untreated cells (105.4 5.9 nm), while others
lacked an electron-dense content (Fig. 6A and D). Thus, the late-
acting effects of nucleozin on vRNP trafficking and titer output
can be correlated with matching effects on virus particle forma-
tion, suggesting a direct link between RNP localization and virus
budding.
DISCUSSION
Independent work in several laboratories has identified nucleozin
and related compounds as drugs that promote the formation of
cytoplasmic NP aggregates, inhibit vRNA synthesis, and effec-
tively interfere with virus replication (13, 15–17). Structural anal-
yses suggest that the drugs act as “molecular staples” that stabilize
NP-NP interactions, presumably either by inducing functionally
inappropriate binding modes that do not normally occur or by
locking ordinarily transient interactions in place so that they be-
come inhibitory. The 50%effective concentration of nucleozin for
overall virus replication is around 15-fold lower than the corre-
sponding concentration required to inhibit transcription by iso-
lated RNPs (15), suggesting that the direct inhibition of vRNA
synthesis is not the primary block to virus replication. Instead,
initial studies hypothesized that the drug caused the cytoplasmic
aggregation of newly translated NP, thereby blocking its nuclear
import and “starving” viral genome replication of the building
blocks required for encapsidation (13, 15–17). However, on the
basis of our time-of-addition experiments and detailed analyses of
individual steps within viral replication, we propose that RNPs,
not NP, are the primary target of the drug and that the sensitive
step is their cytoplasmic transport.
We show that nucleozin shows distinct effects on virus repli-
cation, depending on the time of addition. When added early in
infection, it inhibited the synthesis of viral proteins and all classes
of RNA (Fig. 1).While failure to produce vRNA could result from
a depleted pool of intranuclear NP, viral transcription and trans-
lation are independent of this (4) and a distinct inhibitory mech-
anism must operate here. Furthermore, the inhibitory effect of
nucleozin on overall virus replication could be decoupled from
any reduction of the synthesis of viral mRNA, proteins, or vRNA
by adding the drug later in infection. Tellingly, adding the drug at
4 hpi had no effect on viral protein synthesis, caused an only 2-fold
drop in vRNA accumulation, and yet reduced the output titer by
around 100-fold compared to that in untreated cells (Fig. 1). In-
stead, the drug caused a striking and rapid aggregation of cytoplas-
mic RNPs (Fig. 2, 4, and 5; see Fig. S1 and S2 in the supplemental
material). This blockade of RNP transport also correlated with a
marked reduction in the amount of virus budding, as well as the
formation of abnormally small virus particles (Fig. 6). Notably,
FIG 6 TEM visualization of budding virions in nucleozin-treated cells. A549 cells were infected withWT or NP Y289Hmutant virus, treated with the drug, and
fixed at the time points shown before imaging by TEM. Arrowheads indicate defective budding events (A) Representative images. Scale bars, 100 nm. (B)
Numbers ofWT budding virions were calculated over the whole surface of one side of the cell. (C) Sizes of budding virions from cells infected withWTPR8were
determined (as shown) for at least 30 particles from three independent experiments and plotted as the average the standard error of themean. Nonparametric
statistical analysis values obtained by Kruskal-Wallis analysis of variance with a significance of 95% were calculated with GraphPad Prism. *, P 0.05; **, P
0.01; ***, P 0.001; NS, no statistically significant difference. (D) Gallery of representative budding events with or without nucleozin (NCZ) treatment (1 M,
added at the indicted times postinfection). Arrows indicate defective particles. Images were compiled from three independent experiments.
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however, we saw little effect of drug treatment on intranuclear NP
localization, either onGFP-NPwith or without RNP formation or
on authentic NP (Fig. 2A). We therefore conclude that the late-
acting effect of nucleozin on virus replication is directly attribut-
able to effects on RNP localization.
Regarding the undoubted ability of nucleozin to inhibit earlier
steps in the virus life cycle, given that the drug did not inhibit
mRNA synthesis when added at 2.5 hpi (before large amounts of
mRNA have accumulated) and that we were working at drug con-
centrations substantially below those required to inhibit in vitro
transcription by isolated RNPs, we think it plausible that the tran-
scriptional inhibition observed when the drug was added at 30
min postinfection can also be explained by inhibition of cytoplas-
mic RNP transport, but on the way into the nucleus rather than
away from it. Thus, although NP is regarded primarily as part of
the vRNA synthesis machinery, this study provides proof of the
principle that targeting its role in intracellular trafficking of the
virus genome can lead to effective inhibition of virus replication.
This mechanism has parallels with the block to RNP nuclear ex-
port caused bymitogen-activated protein kinase kinase inhibitors
(39, 40), and it would be interesting to test these compounds for
synergy with nucleozin.
A further striking outcomeof the late-acting effect of nucleozin
was the inclusion of Rab11 in the cytoplasmic aggregates of RNPs
(Fig. 2 and 4; see Fig. S1 in the supplemental material). Since
Rab11 trafficking was not affected by nucleozin in the absence of
vRNPs, it seems likely that the cellular protein is secondarily re-
cruited to the aggregates via its interactionwith RNPs. This argues
against the simple hypothesis that nucleozin disrupts RNP traf-
ficking by breaking interactions with Rab11. Taking all of this into
account suggests a model in which Rab11-vRNP-decorated vesi-
cles are “stapled” together via persistent RNP-RNP interactions
that override ordinarily transient interactions between vesicular
cargos (see Fig. S3 and Movies S4 and S5 in the supplemental
material). Transfection of dominant negative GFP-Rab11 or de-
pletion of endogenous Rab11 siRNA did not prevent these accu-
mulations in cells infected with the WT viruses (data not shown),
suggesting that Rab11 may not be essential for aggregate forma-
tion. While this is consistent with data suggesting that Rab11 in-
teracts with the viral polymerase rather than NP (6, 9), it leaves
open the question of why the aggregates cluster near the nucleus.
The speedwithwhich this occurs suggests that the RNP aggregates
remain attached to microtubules (Fig. 5G) but that the net flow
becomes biased toward the inward (minus-end) direction. Why
the increase in the size of RNP-Rab11 cargo complexes should
favor this direction of travel is not obvious, but it may become
clearer when the motor proteins involved in RNP transport are
identified. Dynein has, however, been implicated in the transport
of “aggresomes,” created by misfolded proteins, so it is possible
that the same mechanism operates here (41).
Nucleozin treatment also inhibited virus budding, leading to
the production ofmarkedly fewer and smaller virus particles (with
the latter potentially because of reduced RNP content) (Fig. 6).
For normal virus budding, all virion components need to meet at
the PM fromwhere amembrane curvature protrudes, followed by
the formation of a neck and finally membrane scission. All three
viral integralmembrane proteins have been implicated in this pro-
cess (42–44). Despite the major effect nucleozin had on Rab11
localization (and thus presumably traffic throughout the recycling
endosomal pathway), we did not detect any drug-induced altera-
tions of the standard exocytic pathway or of the localization of
HA, NA, and M2 (Fig. 5). We therefore favor the hypothesis that
correct trafficking of the viral genome is specifically required to
allow efficient virus assembly and/or budding. This is consistent
with our previous findings of defective budding and RNP traffick-
ing in the absence of normal levels of Rab11 (6, 38). Although the
effect of nucleozin does not help distinguish between a budding
defect resulting primarily from the disruption of Rab11 function
and a secondary effect on RNP localization, observations that vi-
ruses lacking an individual segment or containing disrupted seg-
ment-specific packaging signals produce reduced numbers of par-
ticles (21, 45–47) favor a role for RNP organization in normal
virion formation.
The Rab11 pathway has been implicated in the transport of
progeny RNA from other negative-strand viruses, notably, Sendai
virus and human respiratory syncytial virus, members of the
Paramyxoviridae family (48, 49); hantavirus (50); and hepatitis C
virus, a positive-sense RNA virus in the Flaviviridae family (51).
The common exploitation of a pathway by several circulating vi-
rus families able to infect mammals and on occasion cause severe
disease in humans suggests that the inhibitory strategy described
herein could be applied to other viruses.
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